By understanding and controlling activation of specific dopamine receptors, we showed that the current dopamine pathway drugs can be used in new ways as new therapeutics to treat wet age-related macular degeneration (ARMD) and diabetic retinopathy (DR). It will reduce the chance of a side effect of conventional ARMD or DR therapy, leading to vision loss after the intravitreal injection treatment. . These proposed specific dopaminergic molecules (in particular, dopamine 2 receptor agonists) would prevent side effects of current regimen by avoiding the invasive intravitreal injection as well as help to control blood vessels in the pathophysiology of wet ARMD and DR. This treatment strategy should also reduce the treatment frequency and burden of intravitreal injection in current wet ARMD and DR treatments. It will allow longer-term treatments by mitigating damaging side effects seen in the current intravitreal injection therapy.